Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.57 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.57 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.57 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.57 |
| ▸ | CCR1 | P32246 | 2/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 3/20 | 0.48 |
| ▸ | CMA1 | P23946 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL523865 | 1.00 | PDK1 (0.57) | PDK1PDK2PDK3PDK4CCR1 | |
| SCHEMBL524203 | 0.86 | CCR1 (0.56) | CCR1CAPN1CMA1KMT2ACTSL | |
| SCHEMBL524204 | 0.86 | CCR1 (0.56) | CCR1CAPN1CMA1KMT2ACTSL | |
| SCHEMBL28775136 | 0.85 | PDK1 (0.54) | PDK1PDK2PDK3PDK4CTSL | |
| SCHEMBL28775133 | 0.85 | PDK1 (0.54) | PDK1PDK2PDK3PDK4CTSL | |
| SCHEMBL28775139 | 0.85 | PDK1 (0.54) | PDK1PDK2PDK3PDK4CTSL | |
| SCHEMBL29300886 | 0.82 | PDK1 (0.70) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL953545 | 0.82 | PDK1 (0.70) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL952361 | 0.82 | PDK1 (0.70) | PDK1PDK2PDK3PDK4KMT2A | |
| SCHEMBL15534865 | 0.81 | CCR1 (0.61) | CCR1CAPN1KMT2ACTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417128-B1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES AS ADP RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2016-03-02 | — | — | EP | disclosed |
| US-8288385-B2 | 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-16 | — | — | US | disclosed |
| EP-2417128-A2 | 6-(3-AZA-BICYCLOÝ3.1.0¨HEX-3-YL)-2-PHENYL-PYRIMIDINES | Actelion Pharmaceuticals Ltd. (CH) | 2012-02-15 | — | — | EP | disclosed |
| US-20120028989-A1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES | VIATRIS ASIA PACIFIC PTE. LTD. (SG) | 2012-02-02 | — | — | US | disclosed |
| WO-2010116328-A2 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028989-A1 | 6-(3-AZA-BICYCLO[3.1.0]HEX-3-YL)-2-PHENYL-PYRIMIDINES | P2RY12, P2RY13, P2RY6 | PDK1 3320/4885PDK2 2073/4885PDK3 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.